This meta-analysis has demonstrated that patients with NSCLC and EGFR mutation status have a better response in term of OS when treated with docetaxel compared with checkpoint inhibitor as second- or third-line therapy after disease recurrence or progression during TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.